The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)
Abstract
BACKGROUND: Mucormycosis is a deadly invasive fungal infection whose characteristics are only partially understood. METHODS: Data on mucormycosis obtained in France between 2005 and 2007 from 2 notification systems were merged. The 2008 European Organisation for Research and Treatment of Cancer/Mycoses Study Group definition criteria were applied and risk factors for death were analyzed by hazard ratios (HRs) calculated from the Cox proportional hazards regression model. RESULTS: A total of 101 cases (60 proven, 41 probable), mostly in men (58%) >50 years (mean age, 50.7 ± 19.9) were recorded. Hematological malignancies represented 50% (median time for occurrence, 8.8 months after disease onset), diabetes 23%, and trauma 18% of cases. Sites of infection were lungs (28%; 79% in hematology patients), rhinocerebral (25%; 64% in diabetic patients), skin (20%), and disseminated (18%). Median time between first symptoms and diagnosis was 2 weeks. The main fungal species were Rhizopus oryzae (32%) and Lichtheimia species (29%). In cases where the causative species was identified, R. oryzae was present in 85% of rhinocerebral forms compared with only 17% of nonrhinocerebral forms (P < .001). Treatment consisted of surgery in 59% and antifungals in 87% of cases (liposomal amphotericin B in 61%). Ninety-day survival was 56%; it was reduced in cases of dissemination compared with rhinocerebral (HR, 5.38 [2.0-14.1]; P < .001), pulmonary (HR, 2.2 [1.0-4.7]; P = .04), or skin localization (HR, 5.73 [1.9-17.5]; P = .002); survival was reduced in cases of hematological malignancies compared with diabetes mellitus (HR, 2.3 [1.0-5.2]; P < .05) or trauma (HR, 6.9 [1.6-28.6], P = .008) and if ≥2 underlying conditions (HR, 5.9 [1.8-19.0]; P = .004). Mucormycosis localization remained the only independent factor associated with survival. CONCLUSIONS: This 3-year study performed in one country shows the diverse clinical presentation of mucormycosis with a high prevalence of primary skin infection following trauma and a prognosis significantly influenced by localization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Self-citationEpidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Lass-Florl, C., Bouza, E., Klimko, N., Gaustad, P., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03456.x · Cited by 748
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 555
Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Self-citationThe endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
Almyroudis, N. G., Sutton, D. A., Linden, P., Rinaldi, M. G., Fung, J., & Kusne, S. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01496.x · Cited by 277
Invasive zygomycosis in India: experience in a tertiary care hospital
Chakrabarti, A., Chatterjee, S. S., Das, A., Panda, N., Shivaprakash, M. R., Kaur, A., Varma, S. C., Singhi, S., Bhansali, A., & Sakhuja, V (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.076463 · Cited by 244
Mucormycosis: Emerging Prominence of Cutaneous Infections
Adam, R. D., Hunter, G., DiTomasso, J., & Comerci, G. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.1.67 · Cited by 202
Forty-one recent cases of invasive zygomycosis from a global clinical registry
Ruping, M. J. G. T., Heinz, W. J., Kindo, A. J., Rickerts, V., Lass-Florl, C., Beisel, C., Herbrecht, R., Roth, Y., Silling, G., Ullmann, A. J., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp430 · Cited by 201
Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues
Schwarz, P., Bretagne, S., Gantier, J.-C., Garcia-Hermoso, D., Lortholary, O., Dromer, F., & Dannaoui, E. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.340-349.2006 · Cited by 191
Self-citationRhino-Orbital-Cerebral Zygomycosis in Solid Organ Transplant Recipients
Sun, H., Forrest, G. N., Gupta, K. L., Aguado, J. M., Lortholary, O., Juliá, M. B., Safdar, N., Patel, R., Kusne, S., & Singh, N. (2010) · Transplantation · doi:10.1097/tp.0b013e3181dde8fc · Cited by 122
Self-citationPagano, L., Valentini, C. G., Posteraro, B., Girmenia, C., Ossi, C. M., Pan, A. S., Candoni, A., Nosari, A., Riva, M., Cattaneo, C. M., et al. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.3.322 · Cited by 98
Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases
Shoham, S., Magill, S. S., Merz, W. G., Gonzalez, C. E., Seibel, N. L., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., & Walsh, T. J. (2010) · Medical Mycology · doi:10.3109/13693780903311944 · Cited by 83
Liposomal amphotericin B: what is its role in 2008?
Lanternier, F., & Lortholary, O. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01984.x · Cited by 70
Self-citationAgents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis
Garcia‐Hermoso, D., Alanio, A., Lortholary, O., & Dromer, F. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch121 · Cited by 30
Self-citation
Cited by
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationJeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S. C.-A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.011 · Cited by 1,082
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Self-citationIsavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Metadata
- Authors
- Lanternier, F., Dannaoui, E., Morizot, G., Elie, C., Garcia-Hermoso, D., Huerre, M., Bitar, D., Dromer, F., Lortholary, O., & the French Mycosis Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-13
- Volume
- 54
- Issue
- suppl 1
- Pages
- S35-S43
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1997724791
- Cited by
- 527
- References
- 18
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.